Nervgen Pharma Corp.
NGENNasdaqCIK 1751912HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY2024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (0.36)Diluted EPS, period not labelled, twelve months to 2024-12-31−CAD 0.36 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure | (0.61)Diluted EPS, FY2025, twelve months to 2025-12-31−CAD 0.61 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 2026-06-30 | $8.2m | 4,000,000 | New+4,000,000 | |
| Rock Springs Capital Management LP | 2026-06-30 | $2.5m | 1,208,231 | New+1,208,231 | |
| DAFNA Capital Management LLC | 2026-06-30 | $2.2m | 1,050,000 | New+1,050,000 | |
| Ghisallo Capital Management LLC | 2026-06-30 | $2.1m | 1,000,000 | New+1,000,000 | |
| ARMISTICE CAPITAL, LLC | 2026-06-30 | $1.4m | 678,000 | New+678,000 | |
| LMR Partners LLP | 2026-06-30 | $1.2m | 600,000 | New+600,000 | |
| MARSHALL WACE, LLP | 2026-06-30 | $898.1k | 435,962 | Added+235,603 | |
| UBS Group AG | 2026-06-30 | $782.2k | 379,726 | Added+318,209 | |
| Stonepine Capital Management, LLC | 2026-06-30 | $559.7k | 271,678 | New+271,678 | |
| JANE STREET GROUP, LLC | 2026-06-30 | $557.7k | 270,750 | New+270,750 |
Recent filings
All 41 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2520:30 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-25 | 0001104659-26-111004 |
| 2026-09-2412:27 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-24 | 0001104659-26-110225 |
| 2026-08-1311:31 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-13 | 0001104659-26-095467 |
| 2026-07-0221:23 ET | 6-K | Report of a foreign private issuerPeriod 2026-07-02 | 0001104659-26-080432 |
| 2026-06-0121:29 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-01 | 0001104659-26-069028 |
| 2026-05-2620:35 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-26 | 0001104659-26-066307 |
| 2026-05-2221:24 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-22 | 0001104659-26-065821 |
| 2026-05-1820:19 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-18 | 0001104659-26-063212 |
| 2026-05-1520:28 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-15 | 0001104659-26-062618 |
| 2026-04-2721:05 ET | 6-K | Report of a foreign private issuerPeriod 2026-04-27 | 0001104659-26-049508 |
Latest annual report
Form 40-F for the fiscal year ended Dec 31, 2025Filed Mar 31, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1751912
- Tickers
- NGEN
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- not reported
- Filer category
- <br>Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.